Nanologica AB
The answer first
Does Nanologica beat the market?
No, Nanologica has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 72% of Nordic stocks
- Quality86
- Value99
- Trend1
No. 35 of 195 in healthcare
Max for seven days
Follow Nanologica with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Nanologica
Your first answer is free, no account needed.
Do you own Nanologica, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Nanologica and a few more. Free, no card.
Super Stock+46.4%In short
- Nanologica has fallen 83.7% over the past year, including dividends.
- Overall, Nanologica ranks better than 72% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.5%. The price is 99.3% below its peak now.
What do analysts think of Nanologica?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 72% of Nordic stocks.
No. 35 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 42 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.41
- Asset turnoverSales divided by everything the company owns0.22
- Return on equityProfit divided by equity+12.0%
- Cash conversionOperating cash flow divided by profit−3.03
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 3 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.3
- P/SPrice divided by sales0.9
- P/EPrice divided by earnings2.4
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 191 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−61.0%
- 6 months−75.1%
- 9 months−58.5%
- 12 months−83.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Nanologica
2 funds we follow own Nanologica. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Nanologica
Nanologica AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Nanologica is number 107 of 137 companies in healthcare on Nasdaq Stockholm. Nanologica has not paid a dividend in the past twelve months. Of the three measures in the ranking, Nanologica is strongest on value, better than 99% of Nordic stocks. The share trades in SEK. It has around 72 employees.
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with sulfopropyl groups as ligands; NLAB Idun Q, a strong anion exchanger with a quaternary amine ligand; and NLAB Siv, a non-silica-based media for purif…


See the full analysis of Nanologica.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card